Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cocrystal Pharma, Inc.COCP · Entity 7621 | Chief Executive Officer | June 22, 2020 | June 24, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cocrystal Pharma, Inc.
Report date June 22, 2020 · Filed June 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2030-06-22 | Direct | 200,000 |
Reported balance
After 2020-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-22 · Grant · Acquired 200,000 · Balance 200,000 F1: The stock options are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code. Only $100,000 (or 35,971 options) may first become exercisable by the Reporting Person in each calendar year. F2: The stock options vest as follows: 100,000 stock options will vest on the one year anniversary of the grant date and the remaining 100,000 stock options will vest in eight equal quarterly increments with the first such quarterly increment vesting on September 30, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code. Only $100,000 (or 35,971 options) may first become exercisable by the Reporting Person in each calendar year.
F2: The stock options vest as follows: 100,000 stock options will vest on the one year anniversary of the grant date and the remaining 100,000 stock options will vest in eight equal quarterly increments with the first such quarterly increment vesting on September 30, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2020 Filed Jun 24, 2020 22:12 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001493152-20-011748 · ownership.xml · derivative · entry 1 WILCOX GARY · CIK 0001222257 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-06-22 F1 · security: The stock options are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code. Only $100,000 (or 35,971 options) may first become exercisable by the Reporting Person in each calendar year. F2 · derivative.exercise_date: The stock options vest as follows: 100,000 stock options will vest on the one year anniversary of the grant date and the remaining 100,000 stock options will vest in eight equal quarterly increments with the first such quarterly increment vesting on September 30, 2021. Read SEC document |
| September 21, 2018 Filed Sep 24, 2018 13:00 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001493152-18-013623 · ownership.xml · derivative · entry 1 WILCOX GARY · CIK 0001222257 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-09-20 F1 · security: The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments. F2 · derivative.exercise_date: The stock options are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code. Only $100,000 (or 35,971 options) may first become exercisable by the Reporting Person in each calendar year. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 20:15 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | PurchaseCommon Stock | 10,000 | $0.41 | $4,100.00 |
DisclosureSEC source: 0001415889-16-007050 · form4-09062016_040901.xml · nonDerivative · entry 1 WILCOX GARY · CIK 0001222257 · Director · INTERIM CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 16,948,605 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.